Gyre Therapeutics (GYRE) Competitors $12.56 +0.42 (+3.46%) Closing price 04:00 PM EasternExtended Trading$12.54 -0.02 (-0.12%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GYRE vs. KRYS, RARE, RNA, SWTX, ADMA, OGN, BHVN, ALVO, PTCT, and RYTMShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Krystal Biotech (KRYS), Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), ADMA Biologics (ADMA), Organon & Co. (OGN), Biohaven (BHVN), Alvotech (ALVO), PTC Therapeutics (PTCT), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Krystal Biotech Ultragenyx Pharmaceutical Avidity Biosciences SpringWorks Therapeutics ADMA Biologics Organon & Co. Biohaven Alvotech PTC Therapeutics Rhythm Pharmaceuticals Krystal Biotech (NASDAQ:KRYS) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking. Which has higher valuation and earnings, KRYS or GYRE? Krystal Biotech has higher revenue and earnings than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$241.52M21.75$10.93M$1.77103.18Gyre Therapeutics$113.45M10.35-$92.93MN/AN/A Is KRYS or GYRE more profitable? Krystal Biotech has a net margin of 21.68% compared to Gyre Therapeutics' net margin of -84.57%. Krystal Biotech's return on equity of 7.54% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech21.68% 7.54% 6.97% Gyre Therapeutics -84.57%-118.43%-71.97% Does the media favor KRYS or GYRE? In the previous week, Krystal Biotech had 20 more articles in the media than Gyre Therapeutics. MarketBeat recorded 22 mentions for Krystal Biotech and 2 mentions for Gyre Therapeutics. Krystal Biotech's average media sentiment score of 0.90 beat Gyre Therapeutics' score of 0.33 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gyre Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, KRYS or GYRE? Krystal Biotech has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Does the MarketBeat Community favor KRYS or GYRE? Krystal Biotech received 293 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformKrystal BiotechOutperform Votes29367.51% Underperform Votes14132.49% Gyre TherapeuticsN/AN/A Do analysts prefer KRYS or GYRE? Krystal Biotech presently has a consensus price target of $210.00, suggesting a potential upside of 14.99%. Given Krystal Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Krystal Biotech is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in KRYS or GYRE? 86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 14.1% of Krystal Biotech shares are held by company insiders. Comparatively, 19.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryKrystal Biotech beats Gyre Therapeutics on 14 of the 16 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.17B$6.98B$5.80B$9.14BDividend YieldN/A2.88%5.28%3.98%P/E RatioN/A6.1625.8619.11Price / Sales10.35322.78479.25120.63Price / Cash51.0675.0445.1138.24Price / Book69.786.547.655.12Net Income-$92.93M$138.11M$3.18B$245.96M7 Day Performance6.62%-0.47%-0.06%-0.56%1 Month Performance14.70%1.16%3.26%0.39%1 Year Performance-17.04%-2.34%19.18%15.35% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.248 of 5 stars$12.56+3.5%N/A-21.1%$1.17B$113.45M0.0040KRYSKrystal Biotech4.5264 of 5 stars$154.53-0.2%$206.67+33.7%+55.1%$4.44B$241.52M87.31210Earnings ReportAnalyst ForecastShort Interest ↓News CoverageGap UpRAREUltragenyx Pharmaceutical4.6461 of 5 stars$44.78-1.3%$92.43+106.4%-9.5%$4.14B$522.75M-6.921,276Earnings ReportAnalyst ForecastRNAAvidity Biosciences1.6804 of 5 stars$34.31-1.7%$65.80+91.8%+125.0%$4.09B$9.56M-11.91190SWTXSpringWorks Therapeutics1.3268 of 5 stars$54.00+34.1%$70.00+29.6%+6.4%$4.02B$5.45M-13.92230Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews CoverageGap UpHigh Trading VolumeADMAADMA Biologics3.4621 of 5 stars$16.66-0.3%$21.25+27.6%+204.3%$3.94B$258.21M59.50530Upcoming EarningsNews CoverageOGNOrganon & Co.4.8684 of 5 stars$15.04+2.8%$21.33+41.9%-18.1%$3.87B$6.26B2.9810,000Earnings ReportDividend AnnouncementBHVNBiohaven3.4328 of 5 stars$38.25-0.5%$63.00+64.7%-20.9%$3.87BN/A-4.09239Short Interest ↓ALVOAlvotech2.5078 of 5 stars$12.75-1.2%$18.00+41.2%-26.0%$3.84B$93.38M-6.891,026PTCTPTC Therapeutics3.6604 of 5 stars$49.82+0.7%$57.85+16.1%+94.6%$3.84B$900.66M-8.391,410Analyst DowngradeNews CoverageRYTMRhythm Pharmaceuticals4.1308 of 5 stars$58.47-1.2%$68.09+16.5%+17.8%$3.64B$112.53M-13.50140Analyst ForecastInsider TradeNews Coverage Related Companies and Tools Related Companies Krystal Biotech Competitors Ultragenyx Pharmaceutical Competitors Avidity Biosciences Competitors SpringWorks Therapeutics Competitors ADMA Biologics Competitors Organon & Co. Competitors Biohaven Competitors Alvotech Competitors PTC Therapeutics Competitors Rhythm Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GYRE) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredFeb. 26 Could Send Nvidia’s “Silent Partners” SoaringNvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredBig Tech is Barreling Toward a $17 Trillion ReckoningWhile everyday investors keep piling into names like Nvidia, Apple, and Amazon... the owners of those very com...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
